Pronostics Ltd.
This article was originally published in Start Up
Executive Summary
Pronostics is developing molecular fingerprint profiling technology that it describes as a "digital multiplex solution. Its UltraPlex platform uses microscopic aluminum microparticles, each with a unique physical barcode etched onto the surface. Applications for UltraPlex multiplexed assays include direct immunoassays, sandwich ELISAs, DNA hybridization, activity assays, receptor binding assays, and cell-based assays. The first focus for the technology is autoimmune disease, and three UltraPlex multiplexed assays, ANA, thyroid, and celiac disease, are available.